Alfa Biotech reports flat diagnostic sales:
This article was originally published in Clinica
Executive Summary
Diagnostics sales remained flat in 1994 at Italian company Alfa Biotech. The 35% increase in turnover to Lit 54,000 million ($33 million) at the Alfa Wassermann diagnostics and pharmaceutical subsidiary was due to an increase in pharmaceutical sales following a new product launch. Alfa Biotech's diagnostic performance is typical of Italian companies in this sector given the hostile market conditions and uncertainty surrounding marketing practices.